HOLX News and Press, Hologic Inc. From 12/01/19

This article is part of a series that provides an ongoing analysis of the changes made to Larry Robbins’ 13F portfolio on a quarterly basis. It is based on Robbins’ regulatory 13F Form filed on 11/14/2019. Please visit our Tracking Larry Robbins’ Glenview Capital Manage...

Quick Take Genetron Holdings ( GTH ) has filed to raise gross proceeds of $100 million from a U.S. IPO, according to an F-1 registration statement . The firm provides precision oncology diagnosis, monitoring and research services in China. GTH has grown but that growth is decelerating a...

– More sensitive and specific assays for vaginitis reduce the “incorrect, misguided or prolonged treatment” that can result from older, subjective testing methods – Clinical evidence demonstrating the effectiveness of new FDA-cleared assays for the detection o...

Usually, Once A Pattern Is Well Recognized It Stops Working I am hoping that I caught one before it really emerges. If we have, then we should generate good alpha. I believe I see the logic in it as well, just by examining my own "gut" over the course of the last few weeks. As we break i...

Hologic (NASDAQ: HOLX ) has agreed to sell its Cynosure medical aesthetics business to an affiliate of funds managed by Clayton, Dubilier & Rice for $205M in cash, although certain adjustments at closing will trim the proceeds to ~$138M. More news on: Hologic, Inc., Healthcare stocks...

NEW YORK , Nov. 20, 2019 /PRNewswire/ -- Clayton, Dubilier & Rice today announced an agreement under which CD&R-managed funds will acquire Cynosure, LLC, a leader in medical aesthetics systems and technologies, from Hologic, Inc. (NASDAQ:HOLX). Cynosure develops, manufac...

– Company Plans Accelerated Share Repurchase Program – Hologic, Inc. (Nasdaq: HOLX) announced today that it has entered into a definitive agreement to sell its Cynosure medical aesthetics business to an affiliate of investment funds managed by Clayton, Dubilier & Rice f...

Breakthrough Artificial Intelligence-powered algorithm significantly reduces mammography exam read times without compromising image quality, sensitivity or accuracy 1 , 2 Hologic, Inc. (Nasdaq: HOLX) announced today that the U.S. Food and Drug Administration (FDA) has approved 3DQ...

– First FDA-cleared test for this sexually transmitted bacterium can lead to earlier detection and appropriate treatment – A newly published study demonstrates clinical evidence for the effectiveness of a first-of-its-kind, FDA-cleared assay for the detection of the sexuall...

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 11/05/2019. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...